Plasma Therapy Market Size & Share, by Source (Autologous, Allogenic); Type; Application; End user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Plasma Therapy Market - Regional Analysis

North America Market Insights

North America is the dominant player in the global market, which is expected to capture the largest revenue share of 38.7% by the end of 2035. The existence of notable manufacturers, a robust R&D ecosystem, and increasing public awareness are the fueling factors behind the region’s proprietorship. Testifying such capabilities, the study by NIH in October 2023 surveyed 25 top hospitals in the U.S. and found that PRP injections are available in almost every healthcare facility, priced around USD 350 to USD 2,800 per injection average being USD 800. Further, as there is a broader scope, this growing visibility is attracting higher investments, hence, fostering a greater market expansion.

U.S. in the plasma therapy market is stepping towards domination in the regional dynamics on account of suitable reimbursement policies and the presence of skilled professionals. In this context, the data from the Centers for Medicare & Medicaid Services (CMS) in September 2024 revealed that it is enabling coverage for autologous platelet-rich plasma (PRP) therapy for patients who are encountering chronic non-healing diabetic, pressure, or venous wounds, and when administered within approved clinical research studies. Besides, these offerings are expected to expand wider adoption, thereby significantly supporting growth and innovation in this field.

Canada is also following regional growth in the plasma therapy market extensively attributed to the advancements in regenerative medicine and increasing demand for non-invasive treatments. There has been consistent support from both public and private administrative bodies, whether for reimbursements or product approvals, encouraging more players to operate in this field. In July 2024, CSL Behring declared that it received reimbursement recommendation from the Canadian Agency for Drugs and Technologies in Health (CADTH) for HEMGENIX (etranacogene dezaparvovec), the first gene therapy approved for hemophilia B treatment in the country, hence positively impacting market growth.

Clinical Trials Involving Allogeneic and Stem Cell-Based Therapies 2023 

Source: NIH

APAC Market Insights

Asia Pacific in the plasma therapy market is set to showcase the fastest growth during the assessed tenure, i.e., 2026 to 2035. The region’s progress in this field is productively elevated by the rising disease prevalence, aging demographics, and expanded awareness of regenerative medicine. Besides, the region also benefits from vigorous advancements in plasma processing technologies and the existence of supportive administrative bodies encouraging R&D in this field. Furthermore, the prominent countries such as China, Japan, India, and Australia are witnessing higher demand for plasma-derived therapies, including immunoglobulins, clotting factors, hence fostering a profitable business environment.

China is reinforcing its dominance in the plasma therapy market, supporting increased market revenue owing to the heightened demand for plasma-derived products and evolving technologies in plasma sourcing and refinement. For instance, in July 2025, Apyx Medical Corporation announced the launch of Renuvion in the country, thereby introducing its helium plasma technology, which deliberately expanded the clinical adoption of plasma-based therapies in aesthetic and surgical procedures as well. The product received approval from the National Medical Products Administration, elevating the company’s progress in global market expansion.

India is evolving rapidly in the Asia Pacific’s plasma therapy market due to the presence of continuously expanding PRP applications in orthopedics, dermatology, and other chronic diseases. The country also benefits from supportive government policies that are constantly making efforts to bridge gaps in the healthcare sector. In this regard, the Ministry of Health and Family Welfare in January 2025 introduced a scheme called Ayushman Bharat Digital Mission (ABDM) to create a nationwide digital health ecosystem. This system consists of individual Health IDs for patients, helping integrate treatment tracking. Therefore, the implementation of such moves is expected to facilitate better treatment management.

Clinical Trials Involving Allogeneic and Stem Cell-Based Therapies 2023 

Source: NIH

Europe Market Insights

Europe is showcasing notable growth in the plasma therapy market, effectively propelled by the rising demand for immunoglobulins, advancements in plasma-derived therapies, and expanding infrastructure for blood collection and fractionation. The prominent countries such as Germany, France, and Italy are the major contributors to this expected growth, owing to their supportive regulatory frameworks. For instance, in May 2023, Switzerland-based Regen Lab declared that it received CE certification under EU MDR 2017/745 for its PRP-based medical devices, including REGENKIT, CELLULAR MATRIX fig, and Arthrovisc. This certification displays the safety, quality, and performance of its autologous plasma solutions.

Germany holds a strong position in Europe’s plasma therapy market since the PRP treatments are widely adopted across the country’s vast geography. The country also benefits from its advanced healthcare infrastructure, strong R&D ecosystem, and high technological standards. Therefore, in May 2025, the country’s leading firm, called  Viromed Medical AG, reported that scientists and medical researchers at Hannover Medical School represented the utilization of cold plasma for the treatment of ventilator-associated pneumonia, which showed extremely remarkable in vitro efficacy, 100% and safety results, hence benefiting the overall market growth in the country.

France has gained enhanced recognition in the regional plasma therapy market, readily facilitated by the increasing prevalence of musculoskeletal disorders and chronic wounds among the country’s aging demographics. In this context, Cerus Corporation in May 2025 declared that it received approval from the French National Agency for Medicines and Health Product Safety (ANSM) for its next-generation INTERCEPT illumination device. This system is especially designed to enhance operations and ergonomics in daily blood centers, which comprises touch screen navigation and intuitive software, allowing a steady cash influx in the country’s market.

FDA-Approved Plasma Therapy Devices (2024)

Source: U.S. FDA